基本情報
- CAS
128074-72-6- 標準SMILES
Cl.O.O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O- InChIKey
ARPUHYJMCVWYCZ-UHFFFAOYSA-N- 分子式
- C17H21ClFN3O4
- 平均分子量
- 385.8 g/mol
- 単同位体質量
- 385.120462
概要
Ciprofloxacin hydrochloride hydrate is the monohydrate form of ciprofloxacin monohydrochloride. It has a role as an antiinfective agent, an antibacterial drug, an EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor and a topoisomerase IV inhibitor. It contains a ciprofloxacin hydrochloride (anhydrous).
名称と識別子
- 優先名称
- Ciprofloxacin hydrochloride monohydrate
- IUPAC
- 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;hydrate;hydrochloride
名称と別名
86393-32-0Ciprofloxacin hydrochloride monohydrateCiloxanCiprofloxacin hydrochloride hydrateCiprofloxacin HClCipropolFlociprinProquin XRProquinBay o 9867 monohydrateCetraxalCiflox
名称をさらに表示
Bay-o-9867 monohydrateciprofloxacin monohydrochloride monohydrate4BA73M5E371-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, monohydrochloride, monohydrateCiprofloxacin (as hydrochloride)CHEBI:59936OTOVEL COMPONENT CIPROFLOXACIN HYDROCHLORIDECIPRODEX COMPONENT CIPROFLOXACIN HYDROCHLORIDE
データベース識別子
- CAS
128074-72-6、86393-32-0、86483-48-9- PubChem CID
- 62998
- DTXSID
DTXSID00273974- ChEMBL
CHEMBL1202、CHEMBL4303345- ChEBI
CHEBI:59936- UNII
- 4BA73M5E37
- EC Number
- 617-845-1、658-041-0、849-041-3
物性
構造計算による物性
- 極性表面積
- 73.9 Ų
- 水素結合供与体数
- 4
- 水素結合受容体数
- 8
- 回転可能結合数
- 3
- 重原子数
- 26
- 形式電荷
- 0
- 複雑度
- 571
実験および物理化学的性質
Human Drugs
Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antibacterial Agents; Quinolones; Fluoroquinolones
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
This chemical does not meet GHS hazard criteria for 15.8% (28 of 177) of reports.
Warning
H319 (82.5%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
P264+P265, P273, P280, P305+P351+P338, P337+P317, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 177 reports by companies from 24 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Not Classified
危険有害性情報
Hazard Classes and Categories
Eye Irrit. 2 (82.5%)
Not Classified
Not Classified
毒性情報
Health EffectsInflammation of the skin (exfoliative dermatitis)
Exposure RoutesEye contact; parenteral (intravenous injection); oral. Rapidly and well absorbed from the gastrointestinal tract after oral administration. The absolute bioavailability is approximately 70% with no substantial loss by first pass metabolism.
Toxicity Summary
The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, strand supercoiling repair, and recombination.
Signs and SymptomsThe major adverse effect seen with use of is gastrointestinal irritation, common with many antibiotics.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
化学と産業
薬理情報
Metabolism/Metabolites
Hepatic. Four metabolites have been identified in human urine which together account for approximately 15% of an oral dose. The metabolites have antimicrobial activity, but are less active than unchanged ciprofloxacin. Route of Elimination: Approximately 40 to 50% of an orally administered dose is excreted in the urine as unchanged drug. Half Life: 4 hours
FDA Pharmacological Classification
CIPROFLOXACIN HCL
Fluoroquinolone Antibacterial [EPC]; Fluoroquinolones [CS]; Cytochrome P450 1A2 Inhibitors [MoA]
CIPROFLOXACIN HYDROCHLORIDE
Cytochrome P450 1A2 Inhibitors [MoA]; Quinolone Antimicrobial [EPC]; Quinolones [CS]; Fluoroquinolone Antibacterial [EPC]; Fluoroquinolones [CS]
CIPROFLOXACIN TABLETS
Fluoroquinolones [CS]; Fluoroquinolone Antibacterial [EPC]; Cytochrome P450 1A2 Inhibitors [MoA]
MeSH Pharmacological Classification
Substances that inhibit the growth or reproduction of BACTERIA.
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2.
用途と製造
Uses
For the treatment of the following infections caused by susceptible organisms: urinary tract infections, acute uncomplicated cystitis, chronic bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections (used in combination with metronidazole), infectious diarrhea, typhoid fever (enteric fever), uncomplicated cervical and urethral gonorrhea, and inhalational anthrax (post-exposure).
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…